Novel pharmacologic approaches for the management of diabetic retinopathy

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Diabetic retinopathy is the leading cause of vision loss among working-age people in the United States. The hallmark of diabetic retinopathy is vascular compromise. Increased vascular permeability leads to the development of diabetic macular edema, which is the major cause of vision loss in patients with diabetic retinopathy. Vascular occlusion causes retinal ischemia and subsequent angiogenesis (proliferative diabetic retinopathy), which increases the risk for vitreous hemorrhage and retinal detachment. Over the past 30 years our understanding of the pathophysiology of diabetic retinopathy has evolved greatly and has fostered the development of many novel treatments for this condition. This article will review promising new local and systemic pharmacologic treatments for diabetic macular edema and proliferative diabetic retinopathy.

Original languageEnglish (US)
Pages (from-to)222-227
Number of pages6
JournalMolecular and Cellular Pharmacology
Issue number4
StatePublished - Dec 1 2009


  • Corticosteroid
  • Diabetes
  • Diabetic retinopathy
  • Macular edema
  • Proliferative diabetic retinopathy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Biology


Dive into the research topics of 'Novel pharmacologic approaches for the management of diabetic retinopathy'. Together they form a unique fingerprint.

Cite this